


# GIMEMA LAL2317: scheme

## A. Induction/consolidation, Blinatumomab, MRD study and early SCT



## B. Final MRD-oriented therapy



### Treatment elements



# GIMEMA LAL2317: sample size

## Sample Size

the total number of patients to enroll is 149

## Study duration:

- 24 months (or more if necessary) for patient enrolment (149 patients).
- 32 months for treatment therapy (231 days for induction, consolidation and re-induction therapy + 24 months of maintenance).
- 12 months of follow-up.

Total: 68 months

# **GIMEMA LAL2317: enrollment**

Ad oggi, 90 pazienti arruolati.

La data di chiusura arruolamento prevista è agosto 2020, a meno che non si riesca a raggiungere prima il numero totale dei pazienti.